Genmab — April 2019

[E_L]

We and Genmab are also evaluating TV in combination with other agents to inform our strategy of moving TV into earlier lines of cervical cancer. Further, we are enrolling patients in trials of TV with other solid tumors.

[E_L]

end quote

[Bulder]

Nice to hear that they have designed the trial for RTOR.

[JohnW]

Thanks E L. That was good news.

[E_L]

@Bulder yes, that shows good faith

[JKY_VH]

Tak E L

[E_L]

@Sukkeralf did you see BMS say anything about Humax IL8 in their earnings?

[Sukkeralf]

I havent looked but would guess not

[bibob]

God formiddag fra 10 km højde på vej sydpå. :-). Jeg kan se Genmab også lettede på vej nordpå. :-).

[E_L]

ok, just because you came with the links just after their earnings

[E_L]

Dr. Durie on Dara SC in the middle of the video
(again nothing we don't know...) https://www.youtube.com/watch?v=a8_MB7o0MZo

[Sukkeralf]

Bulder RTOR ?

[Sukkeralf]

From SG transcript: GSK has some fantastic data in multiple myeloma with the BCMA antibody drug conjugate. And what we hear from them is they're planning to submit in the second half of this year. And we're delighted through the impact in multiple myeloma. That is a potential large market. And they also are doing many other trials, including frontline. And so, that potentially could be a really big drug for GSK and really beneficial to patients and to Seattle genetics.

[Solsen]

Hvis GK er lige så dygtige til at arbejde med BCMA stoffet sim Ofatumumab er der intet at frygte.

[Sukkeralf]

(clinicaltrials.gov)

[Sukkeralf]

Indtil videre i de lidt senere linier, men desværre ingen kombi med Dara

[Solsen]

Gætter vi på MAIA approval i dag ?

[Sukkeralf]

ja eller over weekenden

[Bulder]

Sukkeralf: PR kræver ikke noget særligt studiedesign. Man indsender hele møllen på een gang. Når de omtaler et særligt design, antager jeg at det er motiveret i RTOR. Hvad ellers?

[Bulder]

FDA's accelerated approval mechanism